| A Real-World Study of JT001 for COVID-19 (NCT06142201) | Shanghai Vinnerna Biosciences Co., Ltd. | 2023-08-31 |
| Effect of Pharmacokinetics in Healthy Chinese Subjects (NCT06005714) | Shanghai Vinnerna Biosciences Co., Ltd. | 2023-08-15 |
| A Study in Subjects With Liver Function Injury and Subjects With Normal Liver Function (NCT06093230) | Shanghai Vinnerna Biosciences Co., Ltd. | 2023-07-28 |
| A Study in Elderly Chinese Subjects With Underlying Diseases (NCT06093308) | Shanghai Vinnerna Biosciences Co., Ltd. | 2023-07-12 |
| A Study in Subjects With Renal Impairment Compared to Subjects With Normal Renal Function (NCT05895812) | Shanghai Vinnerna Biosciences Co., Ltd. | 2023-05-08 |
| The Mass Balance Study of [14C]JT001 (NCT05802810) | Shanghai Vinnerna Biosciences Co., Ltd. | 2023-03-18 |
| JT001 (VV116) for the Treatment of COVID-19 (NCT05582629) | Shanghai Vinnerna Biosciences Co., Ltd. | 2022-10-21 |
| A Real-world Retrospective Study of Disease Outcomes in Non-severe COVID-19 Patient (NCT05489874) | Shanghai Vinnerna Biosciences Co., Ltd. | 2022-07-14 |
| Evaluate the Pharmacokinetics, Safety and Tolerability of JT001 Tablets (NCT05355077) | Shanghai Vinnerna Biosciences Co., Ltd. | 2022-05-02 |
| Efficacy and Safety of JT001 (VV116) Compared With Favipiravir (NCT05279235) | Shanghai Vinnerna Biosciences Co., Ltd. | 2022-03-14 |